|
業務類別
|
-- |
|
業務概覽
|
PhaseRx Inc is a biopharmaceutical company. It is developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy, or i-ERT. The approach is enabled by proprietary Hybrid messenger RNA, or mRNA, Technology platform, which allows synthesis of the missing enzyme inside the cell. The product portfolio targets the three urea cycle disorders ornithine transcarbamylase deficiency, or OTCD, argininosuccinate lyase deficiency, or ASL deficiency, and argininosuccinate synthetase deficiency, or ASS1 deficiency. |
| 公司地址
| 410 West Harrison Street, Suite 300, Seattle, WA, USA, 98119 |
| 電話號碼
| +1 206 805-6300 |
| 傳真號碼
| -- |
| 公司網頁
| http://www.phaserx.com |
| 員工數量
| 21 |
| Dr. Robert W. Overell,PhD |
Director, President, Secretary, Chief Executive Officer and Principal Accounting Officer |
-- |
26/09/2017 |
| Gordon C. Brandt,M.D. |
Chief Medical Officer |
-- |
13/04/2017 |
|
|
| Ms. Michelle Griffin |
Independent Director |
13/04/2017 |
| Dr. John A. Schmidt,Jr |
Independent Director |
13/04/2017 |
| Peggy V. Phillips |
Independent Director |
13/04/2017 |
| Dr. Steven Gillis |
Chairman of the Board |
13/04/2017 |
| Dr. Robert W. Overell,PhD |
Director, President, Secretary, Chief Executive Officer and Principal Accounting Officer |
26/09/2017 |
| Paul H. Johnson,PhD |
Director |
13/04/2017 |
| Brian G. Atwood |
Independent Director |
13/04/2017 |
|
|
|
|
